Cras P, Martin J J, Gheuens J
Laboratory of Neuropathology, Born-Bunge Foundation, University of Antwerp, Wilrijk, Belgium.
Acta Neuropathol. 1988;75(4):377-84. doi: 10.1007/BF00687791.
A large series of central and peripheral nervous system tumors was studied for the presence of glial fibrillary acidic protein (GFAP) and gamma-enolase (neuron-specific enolase, NSE), using specific monoclonal antibodies (mAbs). Occurrence in and specificity of GFAP to glial and mixed tumors was confirmed and depended on the malignancy grade and features such as meningeal invasion. Using a well-characterized mAb, gamma-enolase was demonstrated in neuronal, as well as in a whole range of non-neuronal tumors. This lack of specificity of gamma-enolase prohibits its use as an exclusive neuronal marker. Nevertheless quantization or comparison with other types of enolases could still prove to be useful in well-defined situations. The advantages inherent to mAbs and a highly sensitive detection system turn GFAP stainings into a specific and readily reproducible technique.
利用特异性单克隆抗体(mAb),对大量中枢神经系统和周围神经系统肿瘤进行了研究,以检测其中是否存在胶质纤维酸性蛋白(GFAP)和γ-烯醇化酶(神经元特异性烯醇化酶,NSE)。GFAP在胶质细胞瘤和混合性肿瘤中的存在及其特异性得到了证实,且取决于恶性程度和诸如脑膜浸润等特征。使用一种特性明确的单克隆抗体,在神经元肿瘤以及一系列非神经元肿瘤中均检测到了γ-烯醇化酶。γ-烯醇化酶缺乏特异性,因此不能将其用作唯一的神经元标志物。然而,在明确界定的情况下,对γ-烯醇化酶进行定量分析或与其他类型的烯醇化酶进行比较仍可能有用。单克隆抗体固有的优势以及高灵敏度检测系统,使得GFAP染色成为一种特异性强且易于重复的技术。